Using Statins To Lower Cholesterol May Be More Beneficial Way To Prevent Heart Attack And Stroke – Part 2 of 3
But statins may also promote people with a lower risk, according to Dr Mark Hlatky, professor of health research and policy and of cardiovascular medicine at Stanford University School of Medicine in Stanford, Calif, and colleagues. Hlatky’s line-up set out to determine the cost-effectiveness of three statin therapy approaches in patients with normal cholesterol levels and no evidence of heart disease or diabetes: following current guidelines; conducting CRP screening in patients who don’t come together current statin treatment guidelines and offering statins to those with elevated CRP levels; and providing statin therapy based on a patient’s cardiovascular peril alone, with no CRP testing.
The researchers analyzed which of the three approaches met the generally accepted cost-effectiveness threshold of no more than $50000 per quality-adjusted life-year. They found that statin therapy based on cardiovascular hazard alone, without CRP testing, was the most cost-effective strategy.